We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+3.08%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.24B
AUM Growth
+$30.7M
(+2.5%)
Cap. Flow
+$41.5M
Cap. Flow
% of AUM
3.35%
Top 10 Holdings %
Top 10 Hldgs %
87.1%
Holding
32
New
2
Increased
4
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NovoCure
NVCR
|
+$33.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$12.1M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$5.38M |
| 4 |
STAAR Surgical
STAA
|
+$1.67M |
| 5 |
Relmada Therapeutics
RLMD
|
+$526K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$9.42M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$1.3M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$1.02M |
| 4 |
Prothena Corp
PRTA
|
+$408K |
| 5 |
PKBO
Peak Bio, Inc. Common Stock
PKBO
|
+$314K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
26
DELISTED
Kezar Life Sciences
KZR
| $1.61M | 0.13% |
65,620
| – | – |
|
27
Aldeyra Therapeutics
ALDX
$91.7M
| $1.35M | 0.11% |
160,800
| – | – |
|
|
GRTS
28
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.3M | 0.1% |
666,127
| – | – |
|
29
Tactile Systems Technology
TCMD
$555M
| $676K | 0.05% |
27,100
| – | – |
|
30
UroGen Pharma
URGN
$2.39B
| $254K | 0.02% |
24,500
| – | – |
|
|
PRVB
31
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| – | – |
-390,800
| Closed | -$9.42M |
|
|
PKBO
32
DELISTED
Peak Bio, Inc. Common Stock
PKBO
| – | – |
-497,528
| Closed | -$314K |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q2 2023 Portfolio in Review
As of Q2 2023, Palo Alto Investors held 32 positions worth $1.24B, up 2.5% from $1.21B the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Palo Alto Investors deployed $41.5M of net new capital in Q2 2023, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 94,030 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $1.3M trimmed.
- Palo Alto Investors's largest Q2 2023 buy was Sarepta Therapeutics: 94,030 shares worth $10.8M.
- Palo Alto Investors added most to NovoCure in Q2 2023, an estimated $33.9M increase.
- Palo Alto Investors's biggest Q2 2023 reduction was Revance Therapeutics, Inc., cutting an estimated $1.3M.
- Palo Alto Investors fully exited Provention Bio, Inc. Common Stock in Q2 2023, selling an estimated $9.42M.
- Palo Alto Investors's ten largest holdings make up 87% of its $1.24B portfolio in Q2 2023.
- Palo Alto Investors opened 2 new positions and closed 2 in Q2 2023.
- Palo Alto Investors's portfolio value rose 2.5% quarter-over-quarter to $1.24B.
Based on Palo Alto Investors's 13F filing for Q2 2023, filed 14 Aug 2023.